PL3577135T3 - Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 - Google Patents

Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5

Info

Publication number: PL3577135T3
Authority: PL; Poland
Prior art keywords: prevention; treatment; pharmaceutical composition; related diseases; diseases
Prior art date: 2017-01-31

Application number

PL18710159.7T

Other languages

English (en)

Inventor

Kenji SHINOMIYA

Koichiro YONEYAMA

Norihito Shibahara

Yoshinori Tsuboi

Taku FUKUZAWA

Kenta HARAYA

Zenjiro Sampei

Katrijn BOGMAN

Jean Eric CHAROIN

Original Assignee

Chugai Seiyaku Kabushiki Kaisha

F. Hoffmann-La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-01-31

Filing date

2018-01-31

Publication date

2023-12-04

2017-01-31 Priority claimed from SG10201700775YA external-priority patent/SG10201700775YA/en

2017-07-20 Priority claimed from SG10201705954VA external-priority patent/SG10201705954VA/en

2018-01-31 Application filed by Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche Ag filed Critical Chugai Seiyaku Kabushiki Kaisha

2023-12-04 Publication of PL3577135T3 publication Critical patent/PL3577135T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Dermatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)

PL18710159.7T 2017-01-31 2018-01-31 Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 PL3577135T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SG10201700775YA SG10201700775YA (en)	2017-01-31	2017-01-31	A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
SG10201705954VA SG10201705954VA (en)	2017-07-20	2017-07-20	A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PCT/JP2018/003193 WO2018143266A1 (en)	2017-01-31	2018-01-31	A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Publications (1)

Publication Number	Publication Date
PL3577135T3 true PL3577135T3 (pl)	2023-12-04

Family

ID=61617058

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18710159.7T PL3577135T3 (pl)	2017-01-31	2018-01-31	Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5

Country Status (19)

Country	Link
US (3)	US20190367599A1 (pl)
EP (2)	EP4223774A3 (pl)
JP (4)	JP6383122B2 (pl)
KR (4)	KR20230043247A (pl)
CN (1)	CN110167961A (pl)
AU (2)	AU2018215039B2 (pl)
BR (1)	BR112019015426A2 (pl)
CA (1)	CA3051389A1 (pl)
CR (2)	CR20190403A (pl)
ES (1)	ES2947735T3 (pl)
IL (2)	IL307593A (pl)
MX (2)	MX2019007749A (pl)
MY (1)	MY201148A (pl)
PH (1)	PH12019501706A1 (pl)
PL (1)	PL3577135T3 (pl)
SG (2)	SG10201908697XA (pl)
TW (3)	TWI658834B (pl)
UA (1)	UA129282C2 (pl)
WO (1)	WO2018143266A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104761637B (zh)	2006-03-31	2021-10-15	中外制药株式会社	调控抗体血液动力学的方法
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en)	2008-04-11	2015-12-02	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI654204B (zh)	2010-11-30	2019-03-21	Chugai Seiyaku Kabushiki Kaisha	具有鈣依存性的抗原結合能力之抗體
SG10201710322VA (en)	2014-12-19	2018-02-27	Chugai Pharmaceutical Co Ltd	Anti-c5 antibodies and methods of use
NZ730607A (en)	2014-12-19	2022-07-01	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016125495A1 (en)	2015-02-05	2016-08-11	Chugai Seiyaku Kabushiki Kaisha	Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
AU2017269839A1 (en)	2016-05-27	2018-11-22	Alexion Pharmaceuticals, Inc.	Methods for treatment of refractory generalized myasthenia gravis
WO2017218515A1 (en)	2016-06-14	2017-12-21	Regeneron Pharmaceuticals, Inc.	Anti-c5 antibodies and uses thereof
BR112019001902A2 (pt)	2016-08-05	2019-07-09	Chugai Seiyaku Kabushiki Kaisha	composição para profilaxia ou tratamento de doenças relacionadas à il-8
EP3700928A1 (en)	2017-10-26	2020-09-02	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
MX2020006113A (es)	2017-12-13	2020-08-24	Regeneron Pharma	Combinaciones de anticuerpos anti-c5 y usos de las mismas.
JP7577542B2 (ja)	2018-06-04	2024-11-05	アレクシオンファーマシューティカルズ，インコーポレイテッド	小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
MX2021004994A (es) *	2018-10-30	2021-06-15	Alexion Pharma Inc	Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
CN115068604A (zh) *	2019-07-31	2022-09-20	豪夫迈·罗氏有限公司	通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
CA3144921A1 (en) *	2019-07-31	2021-02-04	F. Hoffmann-La Roche Ag	Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
AU2020369581A1 (en) *	2019-10-25	2022-04-21	Regeneron Pharmaceuticals, Inc.	Dosing regimens for treating or preventing C5-associated diseases
CN116194478A (zh)	2020-06-24	2023-05-30	阿雷克森制药公司	皮下（sc）施用抗c5抗体治疗补体相关病症
US20230340140A1 (en) *	2020-08-12	2023-10-26	Innate Pharma	Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
WO2022087339A1 (en) *	2020-10-23	2022-04-28	Alexion Pharmaceuticals, Inc.	Methods of treating patients having complement disorders using anti-c5 antibodies
JP2024060738A (ja)	2022-10-20	2024-05-07	セイコーエプソン株式会社	気体分離膜

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
ATE255131T1 (de)	1991-06-14	2003-12-15	Genentech Inc	Humanisierter heregulin antikörper
JPH08511420A (ja)	1993-06-16	1996-12-03	セルテック・セラピューテイクス・リミテッド	抗体
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
IL138608A0 (en)	1998-04-02	2001-10-31	Genentech Inc	Antibody variants and fragments thereof
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
KR100940380B1 (ko)	1999-01-15	2010-02-02	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP2113516B1 (en)	2000-10-10	2014-05-21	Genentech, Inc.	Antibodies against C5 inhibiting type II endothelial cell activation
CA2457461C (en)	2001-08-17	2013-12-24	Tanox, Inc.	Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
ITMI20021527A1 (it)	2002-07-11	2004-01-12	Consiglio Nazionale Ricerche	Anticorpi anti componente c5 del complemento e loro uso
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (en)	2002-12-16	2008-07-16	Genentech, Inc.	Immunoglobulin variants and uses thereof
US20070116710A1 (en)	2004-02-03	2007-05-24	Leonard Bell	Methods of treating hemolytic anemia
US20050169921A1 (en) *	2004-02-03	2005-08-04	Leonard Bell	Method of treating hemolytic disease
PT1737891E (pt)	2004-04-13	2013-04-16	Hoffmann La Roche	Anticorpos anti p-selectina
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
ES2965283T3 (es)	2006-03-15	2024-05-28	Alexion Pharma Inc	Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
EP2275443B1 (en)	2008-04-11	2015-12-02	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
PY09026846A (es)	2008-08-05	2015-09-01	Novartis Ag	Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US9447176B2 (en)	2008-11-10	2016-09-20	Alexion Pharmaceuticals, Inc.	Methods and compositions for treating complement-associated disorders
BR112012022917A2 (pt)	2010-03-11	2017-01-10	Pfizer	anticorpos com ligação a antígeno dependente de ph
TWI667257B (zh)	2010-03-30	2019-08-01	中外製藥股份有限公司	促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
ME03043B (me) *	2013-03-14	2018-10-20	Alnylam Pharmaceuticals Inc	Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu
EP3473272A1 (en) *	2013-03-29	2019-04-24	Alexion Pharmaceuticals, Inc.	Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
NZ711451A (en) *	2014-03-07	2016-05-27	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
SG10201710322VA (en) *	2014-12-19	2018-02-27	Chugai Pharmaceutical Co Ltd	Anti-c5 antibodies and methods of use
WO2016209956A1 (en) *	2015-06-26	2016-12-29	Alexion Pharmaceuticals, Inc.	A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
US20190023775A1 (en)	2016-01-11	2019-01-24	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-c5 antibodies for treatment
WO2017132259A1 (en)	2016-01-25	2017-08-03	Shire Human Genetic Therapies, Inc.	Anti-c5 antibodies with enhanced ph switch

2018
- 2018-01-31 CR CR20190403A patent/CR20190403A/es unknown
- 2018-01-31 EP EP23165354.4A patent/EP4223774A3/en active Pending
- 2018-01-31 AU AU2018215039A patent/AU2018215039B2/en active Active
- 2018-01-31 CR CR20220563A patent/CR20220563A/es unknown
- 2018-01-31 ES ES18710159T patent/ES2947735T3/es active Active
- 2018-01-31 IL IL307593A patent/IL307593A/en unknown
- 2018-01-31 MY MYPI2019004320A patent/MY201148A/en unknown
- 2018-01-31 MX MX2019007749A patent/MX2019007749A/es unknown
- 2018-01-31 BR BR112019015426-4A patent/BR112019015426A2/pt unknown
- 2018-01-31 KR KR1020237009640A patent/KR20230043247A/ko not_active Ceased
- 2018-01-31 KR KR1020197004219A patent/KR102365871B1/ko active Active
- 2018-01-31 US US16/480,047 patent/US20190367599A1/en not_active Abandoned
- 2018-01-31 JP JP2018014743A patent/JP6383122B2/ja active Active
- 2018-01-31 UA UAA201909498A patent/UA129282C2/uk unknown
- 2018-01-31 SG SG10201908697X patent/SG10201908697XA/en unknown
- 2018-01-31 KR KR1020227005327A patent/KR102514175B1/ko active Active
- 2018-01-31 IL IL268327A patent/IL268327B2/en unknown
- 2018-01-31 KR KR1020187009861A patent/KR101949891B1/ko active Active
- 2018-01-31 TW TW107103450A patent/TWI658834B/zh active
- 2018-01-31 EP EP18710159.7A patent/EP3577135B1/en active Active
- 2018-01-31 CN CN201880005975.XA patent/CN110167961A/zh active Pending
- 2018-01-31 SG SG11201801401UA patent/SG11201801401UA/en unknown
- 2018-01-31 WO PCT/JP2018/003193 patent/WO2018143266A1/en not_active Ceased
- 2018-01-31 CA CA3051389A patent/CA3051389A1/en active Pending
- 2018-01-31 PL PL18710159.7T patent/PL3577135T3/pl unknown
- 2018-01-31 TW TW108110617A patent/TWI828672B/zh active
- 2018-01-31 TW TW112148241A patent/TW202412841A/zh unknown
- 2018-06-22 JP JP2018118937A patent/JP7141865B2/ja active Active
2019
- 2019-06-26 MX MX2022012931A patent/MX2022012931A/es unknown
- 2019-07-24 PH PH12019501706A patent/PH12019501706A1/en unknown
2020
- 2020-07-14 US US16/928,129 patent/US20200407432A1/en not_active Abandoned
2022
- 2022-09-12 JP JP2022144425A patent/JP7581292B2/ja active Active
2023
- 2023-03-10 US US18/181,641 patent/US20230250162A1/en active Pending
2024
- 2024-08-23 AU AU2024216280A patent/AU2024216280A1/en not_active Abandoned
- 2024-10-30 JP JP2024190237A patent/JP2025016617A/ja active Pending

Also Published As

Publication number	Publication date
AU2018215039B2 (en)	2024-06-13
AU2024216280A1 (en)	2024-09-12
CR20190403A (es)	2019-10-10
TW202412841A (zh)	2024-04-01
BR112019015426A2 (pt)	2020-05-26
NZ756629A (en)	2025-09-26
EP3577135B1 (en)	2023-04-19
KR20190104982A (ko)	2019-09-11
KR101949891B1 (ko)	2019-02-19
JP2022168209A (ja)	2022-11-04
JP6383122B2 (ja)	2018-08-29
UA129282C2 (uk)	2025-03-12
TWI658834B (zh)	2019-05-11
TW201831201A (zh)	2018-09-01
JP2018141025A (ja)	2018-09-13
JP2025016617A (ja)	2025-02-04
AU2018215039A1 (en)	2019-09-19
IL268327B1 (en)	2025-05-01
EP4223774A2 (en)	2023-08-09
TW201922286A (zh)	2019-06-16
KR20180099625A (ko)	2018-09-05
KR20220027265A (ko)	2022-03-07
US20230250162A1 (en)	2023-08-10
CA3051389A1 (en)	2018-08-09
EP4223774A3 (en)	2023-09-27
RU2019126664A (ru)	2021-03-02
KR20230043247A (ko)	2023-03-30
KR102514175B1 (ko)	2023-03-29
PH12019501706A1 (en)	2020-03-16
CN110167961A (zh)	2019-08-23
IL268327B2 (en)	2025-09-01
JP2018123125A (ja)	2018-08-09
KR102365871B1 (ko)	2022-02-21
JP7141865B2 (ja)	2022-09-26
SG10201908697XA (en)	2019-10-30
IL268327A (en)	2019-09-26
MX2022012931A (es)	2022-11-08
US20200407432A1 (en)	2020-12-31
WO2018143266A1 (en)	2018-08-09
IL307593A (en)	2023-12-01
RU2019126664A3 (pl)	2021-05-25
TWI828672B (zh)	2024-01-11
US20190367599A1 (en)	2019-12-05
JP7581292B2 (ja)	2024-11-12
MY201148A (en)	2024-02-07
EP3577135A1 (en)	2019-12-11
ES2947735T3 (es)	2023-08-17
SG11201801401UA (en)	2018-09-27
MX2019007749A (es)	2019-09-09
CR20220563A (es)	2022-12-07

Publication	Publication Date	Title
ZA202004025B (en)	2021-09-29	Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
ZA201908165B (en)	2023-07-26	Compounds for the prevention and treatment of diseases and the use thereof
IL268327A (en)	2019-09-26	A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases
IL256085B (en)	2021-02-28	A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment
IL255509B (en)	2021-04-29	Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
PL3829628T3 (pl)	2024-08-19	Kompozycja farmaceutyczna do zastosowania w leczeniu lub zapobieganiu chorobie związanej z C5
IL274578A (en)	2020-06-30	Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
IL254142B (en)	2022-05-01	Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
IL272097A (en)	2020-03-31	Compounds for the prevention and treatment of medical disorders and their uses
IL281585B (en)	2022-04-01	Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
IL272495A (en)	2020-03-31	Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
IL275525A (en)	2020-08-31	A pharmaceutical preparation for the treatment of cancer
HUE045532T2 (hu)	2020-01-28	Preventív és/vagy terápiás szer immunbetegségekre
IL280389A (en)	2021-03-01	Bile acid receptor modulators conjugated to G.1 protein and methods of using them
EP3338771A4 (en)	2019-05-08	PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF TRAMADOL-ETORICOXIB CHLORHYDRATE FOR THE TREATMENT OF PAIN
HUE047272T2 (hu)	2020-04-28	Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
SG11202103070VA (en)	2021-04-29	Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases
IL265976A (en)	2019-06-30	Use of a compound, pharmaceutical preparation and therapeutic method for the treatment or prevention of convulsions
IL259383A (en)	2018-07-31	A compound for use in the prevention and treatment of neurodegenerative diseases
PT3191112T (pt)	2019-06-27	Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura
ES3066523T3 (en)	2026-05-13	Pharmaceutical composition comprising vitamin k2 for use in the treatment or prevention of melanoma
IL257689A (en)	2018-04-30	Pharmacological preparations and methods for the treatment of diseases associated with hypoxia
PL3352777T3 (pl)	2022-02-07	Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona
GB201718838D0 (en)	2017-12-27	Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201712742D0 (en)	2017-09-20	Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases